Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

α1-Antitrypsin deficiency and chronic respiratory disorders.

Cazzola M, Stolz D, Rogliani P, Matera MG.

Eur Respir Rev. 2020 Feb 12;29(155). pii: 190073. doi: 10.1183/16000617.0073-2019. Print 2020 Mar 31. Review.

2.

Severe Asthma and Biological Therapy: When, Which, and for Whom.

Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M.

Pulm Ther. 2019 Dec 26. doi: 10.1007/s41030-019-00109-1. [Epub ahead of print] Review.

PMID:
32048241
3.

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Pulm Ther. 2019 Dec;5(2):117-126. doi: 10.1007/s41030-019-00102-8. Epub 2019 Nov 2. Review.

4.

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life.

Sposato B, Camiciottoli G, Bacci E, Scalese M, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Masieri S, Corsico A, Scichilone N, Baglioni S, Murgia N, Folletti I, Bardi G, Grosso A, Cameli P, Latorre M, Musarra A, Bargagli E, Ricci A, Pelaia G, Paggiaro P, Rogliani P.

Pulm Pharmacol Ther. 2020 Jan 21;61:101899. doi: 10.1016/j.pupt.2020.101899. [Epub ahead of print]

PMID:
31972327
5.

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics.

Principe S, Benfante A, Calzetta L, Rogliani P, Scichilone N.

World Allergy Organ J. 2019 Nov 6;12(11):100081. doi: 10.1016/j.waojou.2019.100081. eCollection 2019 Nov.

6.

A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study.

Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P.

Pulm Pharmacol Ther. 2020 Feb;60:101883. doi: 10.1016/j.pupt.2019.101883. Epub 2019 Dec 26.

7.

The future of bronchodilation: looking for new classes of bronchodilators.

Cazzola M, Rogliani P, Matera MG.

Eur Respir Rev. 2019 Dec 23;28(154). pii: 190095. doi: 10.1183/16000617.0095-2019. Print 2019 Dec 31. Review.

8.

Pharmacology and Therapeutics of Bronchodilators Revisited.

Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M.

Pharmacol Rev. 2020 Jan;72(1):218-252. doi: 10.1124/pr.119.018150. Review.

PMID:
31848208
9.

Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations.

Liccardi G, Calzetta L, Milanese M, Bilò MB, Rogliani P.

J Investig Allergol Clin Immunol. 2019 Dec;29(6):472-473. doi: 10.18176/jiaci.0429. No abstract available.

10.

Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study.

Contoli M, Rogliani P, Di Marco F, Braido F, Corsico AG, Amici CA, Piro R, Sarzani R, Lessi P, Scognamillo C, Scichilone N, Santus P; SAT Study Group.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619888128. doi: 10.1177/1753466619888128.

11.

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience.

Cefalo M, Puxeddu E, Sarmati L, Paterno G, Fontana C, Nasso D, Pane G, De Bellis E, Palmieri R, Buzzati E, Meconi F, Laureana R, Casciani P, Zizzari AG, Rogliani P, de Fabritiis P, Maurillo L, Buccisano F, Cantonetti M, Arcese W, Venditti A, Del Principe MI.

Mediterr J Hematol Infect Dis. 2019 Nov 1;11(1):e2019065. doi: 10.4084/MJHID.2019.065. eCollection 2019.

12.

Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.

Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L.

Br J Pharmacol. 2019 Oct 29. doi: 10.1111/bph.14909. [Epub ahead of print]

PMID:
31660611
13.

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.

Calzetta L, Matera MG, Cazzola M, Rogliani P.

Adv Ther. 2019 Dec;36(12):3291-3298. doi: 10.1007/s12325-019-01119-w. Epub 2019 Oct 25.

14.

The impact of comorbidities on severe asthma.

Rogliani P, Sforza M, Calzetta L.

Curr Opin Pulm Med. 2020 Jan;26(1):47-55. doi: 10.1097/MCP.0000000000000640.

PMID:
31644439
15.

Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.

Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P.

Pulm Pharmacol Ther. 2019 Dec;59:101855. doi: 10.1016/j.pupt.2019.101855. Epub 2019 Oct 19.

PMID:
31639476
16.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2019 Dec;59:101841. doi: 10.1016/j.pupt.2019.101841. Epub 2019 Sep 11.

PMID:
31520718
17.

Pharmacological treatment and current controversies in COPD.

Cazzola M, Rogliani P, Stolz D, Matera MG.

F1000Res. 2019 Aug 29;8. pii: F1000 Faculty Rev-1533. doi: 10.12688/f1000research.19811.1. eCollection 2019. Review.

18.

Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study.

Radovanovic D, Contoli M, Marco FD, Sotgiu G, Pelaia G, Braido F, Corsico AG, Micheletto C, Rogliani P, Scichilone N, Saderi L, Santus P, Solidoro P.

COPD. 2019 Aug;16(3-4):215-226. doi: 10.1080/15412555.2019.1659760. Epub 2019 Sep 9.

PMID:
31500459
19.

Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Expert Opin Investig Drugs. 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990. Epub 2019 Sep 1. Review.

PMID:
31474120
20.

Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.

Vancheri C, Sebastiani A, Tomassetti S, Pesci A, Rogliani P, Tavanti L, Luppi F, Harari S, Rottoli P, Ghirardini A, Kirchgaessler KU, Albera C.

Respir Med. 2019 Sep;156:78-84. doi: 10.1016/j.rmed.2019.08.006. Epub 2019 Aug 13.

PMID:
31445389
21.

Ultra-LABAs for the treatment of asthma.

Cazzola M, Rogliani P, Matera MG.

Respir Med. 2019 Sep;156:47-52. doi: 10.1016/j.rmed.2019.08.005. Epub 2019 Aug 12. Review.

PMID:
31425937
22.

A potential role of triple therapy for asthma patients.

Cazzola M, Puxeddu E, Matera MG, Rogliani P.

Expert Rev Respir Med. 2019 Nov;13(11):1079-1085. doi: 10.1080/17476348.2019.1657408. Epub 2019 Sep 1.

PMID:
31422716
23.

Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?

Liccardi G, Calzetta L, Milanese M, Bilò MB, Rogliani P.

Int Arch Allergy Immunol. 2019;180(2):142-143. doi: 10.1159/000501796. Epub 2019 Aug 14. No abstract available.

PMID:
31412331
24.

Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.

Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG.

Multidiscip Respir Med. 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. eCollection 2019.

25.

Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.

Cazzola M, Puxeddu E, Ora J, Rogliani P.

Mol Diagn Ther. 2019 Oct;23(5):603-614. doi: 10.1007/s40291-019-00413-1. Review.

PMID:
31363933
26.

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment.

Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M.

Pulm Pharmacol Ther. 2019 Oct;58:101828. doi: 10.1016/j.pupt.2019.101828. Epub 2019 Jul 23. Review.

PMID:
31349002
27.

CD71- Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease.

Puxeddu E, Fraboni D, Cillis G, Cavalli F, Buccisano F, Rogliani P.

Am J Respir Crit Care Med. 2019 Dec 1;200(11):1444-1446. doi: 10.1164/rccm.201906-1159LE. No abstract available.

28.

Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis.

Ricci F, Pugliese L, Cavallo AU, Forcina M, De Stasio V, Presicce M, Di Tosto F, Di Donna C, Spiritigliozzi L, Rogliani P, Floris R, Chiocchi M.

Acta Radiol. 2020 Feb;61(2):204-218. doi: 10.1177/0284185119857435. Epub 2019 Jun 25. No abstract available.

PMID:
31237771
29.

Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.

Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D.

Respir Med. 2019 Jul - Aug;154:86-92. doi: 10.1016/j.rmed.2019.06.015. Epub 2019 Jun 18.

PMID:
31228775
30.

Corrigendum to "Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up" [Respir. Med. 153 (2019) 68-75].

Corsico AG, Braido F, Contoli M, Di Marco F, Rogliani P, Scognamillo C, Olivi I, Santus P, Scichilone N, Lazzaro C.

Respir Med. 2019 Nov - Dec;160:105724. doi: 10.1016/j.rmed.2019.06.009. Epub 2019 Jun 13. No abstract available.

PMID:
31202574
31.

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up.

Corsico AG, Braido F, Contoli M, Di Marco F, Rogliani P, Scognamillo C, Olivi I, Santus P, Scichilone N, Lazzaro C.

Respir Med. 2019 Jul;153:68-75. doi: 10.1016/j.rmed.2019.05.017. Epub 2019 May 29. Erratum in: Respir Med. 2019 Jun 12;:.

PMID:
31174106
32.

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.

Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG.

Trends Pharmacol Sci. 2019 Jul;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27. Review.

PMID:
31147200
33.

Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.

Matera MG, Calzetta L, Rogliani P, Cazzola M.

Respir Med. 2019 Jul;153:3-13. doi: 10.1016/j.rmed.2019.05.005. Epub 2019 May 13. Review.

PMID:
31136930
34.

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.

Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L.

Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.

35.

Monoclonal antibodies in severe asthma: is it worth it?

Calzetta L, Matera MG, Rogliani P.

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):517-520. doi: 10.1080/17425255.2019.1621837. Epub 2019 May 23.

PMID:
31104515
36.

Response.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 May;155(5):1079-1080. doi: 10.1016/j.chest.2019.01.028. No abstract available.

PMID:
31060694
37.

Bronchodilators in subjects with asthma-related comorbidities.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Respir Med. 2019 May;151:43-48. doi: 10.1016/j.rmed.2019.04.001. Epub 2019 Apr 3. Review.

PMID:
31047116
38.

Cardiovascular Disease in Chronic Respiratory Disorders and Beyond.

Rogliani P, Cazzola M, Calzetta L.

J Am Coll Cardiol. 2019 May 7;73(17):2178-2180. doi: 10.1016/j.jacc.2018.11.068. No abstract available.

PMID:
31047005
39.

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes.

Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Ricci A, Cresti A, Santus P, Olivieri C, Perrella A, Rogliani P, Paggiaro P; Omalizumab Italian Study Group.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1643-1646. doi: 10.1016/j.jaip.2019.03.006. Epub 2019 Mar 19. No abstract available.

PMID:
30898690
40.

Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.

Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG.

Pulm Pharmacol Ther. 2019 Jun;56:39-50. doi: 10.1016/j.pupt.2019.03.004. Epub 2019 Mar 12.

PMID:
30876907
41.

Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it.

Liccardi G, Calzetta L, Milanese M, Passalacqua G, Rogliani P.

J Allergy Clin Immunol. 2019 Apr;143(4):1657-1658. doi: 10.1016/j.jaci.2018.12.1007. Epub 2019 Feb 10. No abstract available.

PMID:
30745148
42.

Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.

Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J.

Expert Opin Pharmacother. 2019 Apr;20(6):737-750. doi: 10.1080/14656566.2019.1570133. Epub 2019 Feb 1. Review.

PMID:
30707637
43.

The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.

Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messore B, Tomassetti S, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network).

Clin Respir J. 2019 Mar;13(3):166-173. doi: 10.1111/crj.12999.

PMID:
30675755
44.

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17. Review.

PMID:
30660781
45.

Disease awareness in patients with COPD: measurement and extent.

Baiardini I, Rogliani P, Santus P, Corsico AG, Contoli M, Scichilone N, Di Marco F, Lessi P, Scognamillo C, Molinengo G, Ferri F, Patella V, Fiorentino G, Carone M, Braido F.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 17;14:1-11. doi: 10.2147/COPD.S179784. eCollection 2019.

46.

Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis.

Pompeo E, Rogliani P, Atinkaya C, Guerrera F, Ruffini E, Iñiguez-Garcia MA, Peer M, Voltolini L, Caviezel C, Weder W, Opitz I, Cavalli F, Sorge R; ESTS awake thoracic surgery working group.

Interact Cardiovasc Thorac Surg. 2019 May 1;28(5):744-750. doi: 10.1093/icvts/ivy320.

PMID:
30508104
47.

Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents.

Matera MG, Rogliani P, Ora J, Cazzola M.

Expert Opin Pharmacother. 2018 Dec;19(18):2043-2053. doi: 10.1080/14656566.2018.1534957. Epub 2018 Oct 25. Review.

PMID:
30359143
48.

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.

Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 4;13:3115-3130. doi: 10.2147/COPD.S170606. eCollection 2018.

49.

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801586. doi: 10.1183/13993003.01586-2018. Print 2018 Dec.

PMID:
30309975
50.

Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life.

Liccardi G, Calzetta L, Milanese M, Scaglione M, Rogliani P.

Ann Allergy Asthma Immunol. 2018 Oct;121(4):512-513. doi: 10.1016/j.anai.2018.07.039. No abstract available.

PMID:
30290895

Supplemental Content

Loading ...
Support Center